ABSTRACT
Bariatric surgery has gained wide acceptance as a treatment for severe obesity, especially when complicated by type 2 diabetes mellitus (T2DM). Severe obesity has increased more rapidly than overweight and mild obesity [1]. Frequently, severely obese patients present with associated comorbidities, such as T2DM, polycystic ovarian disease, metabolic bone disease, lipid abnormalities, fatty liver, degenerative joint disease, hypertension, gastroesophageal reux disease, and obstructive sleep apnea. Therefore, the mechanism underlying the nutritional and endocrine management of patients after bariatric surgery is an integral component of the overall care of these patients without which the surgery will not lead to a successful outcome.
